2-氯-1-(四氢-2H-吡喃-2-基)-5-(4,4,5,5-四甲基-1,3,2-二氧硼烷)-1H-咪唑 | 1029684-36-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-氯-1-(四氢-2H-吡喃-2-基)-5-(4,4,5,5-四甲基-1,3,2-二氧硼烷)-1H-咪唑
• 中文别名: 2-氯-1-THP-1-H-咪唑-5-硼酸频哪酯
• 英文名称: 2-chloro-1-THP-1H-imidazole-5-boronic acid pinacol ester
• 英文别名: 2-Chloro-1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-imidazole；2-chloro-1-(oxan-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazole
• CAS: 1029684-36-3
• 化学式: C₁₄H₂₂BClN₂O₃
• 分子量: 312.604
• InChiKey: PWGDGTMRINKIRS-UHFFFAOYSA-N

物化性质

• 熔点：
  135 °C
• 沸点：
  466.0±55.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.53
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  45.5
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-氯-1-(四氢-2H-吡喃-2-基)-5-(4,4,5,5-四甲基-1,3,2-二氧硼烷)-1H-咪唑 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 2.0h， 以82%的产率得到1-THP-1-H-咪唑-5-硼酸频那醇酯
  参考文献：
  名称：

  A new boronic-acid based strategy to synthesize 4(5)-(het)aryl-1H-imidazoles

  摘要：

  This paper describes the synthesis of a new N-THP protected 5-(1H)-imidazolyl boronic acid pinacol ester and its use in Suzuki cross-coupling reactions with a wide range of (het)aryl halides to provide 4(5)-(het)aryl-1H-imidazoles. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2008.03.008
• 作为产物：
  描述：

  频哪醇 、 2-chloro-1-(tetrahydropyran-2-yl)-1H-imidazole 在 正丁基锂 、 四甲基乙二胺 、 硼酸三异丙酯 、 溶剂黄146 作用下， 以 四氢呋喃 为溶剂， 反应 5.17h， 以88%的产率得到2-氯-1-(四氢-2H-吡喃-2-基)-5-(4,4,5,5-四甲基-1,3,2-二氧硼烷)-1H-咪唑
  参考文献：
  名称：

  A new boronic-acid based strategy to synthesize 4(5)-(het)aryl-1H-imidazoles

  摘要：

  This paper describes the synthesis of a new N-THP protected 5-(1H)-imidazolyl boronic acid pinacol ester and its use in Suzuki cross-coupling reactions with a wide range of (het)aryl halides to provide 4(5)-(het)aryl-1H-imidazoles. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2008.03.008

文献信息

• PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20180086747A1

  公开（公告）日：2018-03-29

  The present application provides the compounds of formula I or IA or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, m, n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as described herein.

  本申请提供了化合物I或IA的化学式，或其药用可接受盐、异构体、互变异构体或其混合物，其中s、t、m、n、R1、R2、R3、R4、R5、R6和R7如本文所述。
• BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Blaquiere Nicole

  公开号：US20110076292A1

  公开（公告）日：2011-03-31

  Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的苯并噁唑化合物，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和其药学上可接受的盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；而B是与苯并噁唑环融合的吡唑基、咪唑基或三唑基环，可用于抑制脂质激酶，包括p110α和其他PI3K的亚型，并用于治疗由脂质激酶介导的癌症等疾病。揭示了使用公式I中的化合物用于哺乳动物细胞中的体外、体内和原位诊断、预防或治疗此类疾病或相关病理条件的方法。
• Benzoxazepin P13K inhibitor compounds and methods of use
  申请人：F. Hoffman-La Roche AG

  公开号：US08242104B2

  公开（公告）日：2012-08-14

  Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的苯并噁唑环化合物，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物和其药学上可接受的盐，其中：Z1是CR1或N；Z2是CR2或N；Z3是CR3或N；Z4是CR4或N；B是咪唑环、咪唑啉环或三唑啉环融合到苯并噁唑环上，用于抑制脂质激酶，包括p110α和其他PI3K的亚型，并用于治疗由脂质激酶介导的癌症等疾病。还公开了使用公式I中化合物在哺乳动物细胞中进行体外、原位和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• Benzoxazepin PI3K inhibitor compounds and methods of use
  申请人：Genentech, Inc.

  公开号：US08343955B2

  公开（公告）日：2013-01-01

  Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的苯并噁唑环化合物，包括立体异构体、几何异构体、互变异构体、溶剂化物、代谢物及其药学上可接受的盐，其中：Z1是CR1或N；Z2是CR2或N；Z3是CR3或N；Z4是CR4或N；B是嘧唑环、咪唑环或三唑环，融合到苯并噁唑环上，用于抑制脂质激酶，包括p110 alpha和其他PI3K的亚型，并用于治疗由脂质激酶介导的癌症等疾病。公开了使用公式I中的化合物进行哺乳动物细胞的体外、原位和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• [EN] BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PHOSPHATIDYLINOSITOL 3-KINASE
  申请人：GILEAD SCIENCES INC

  公开号：WO2018057808A8

  公开（公告）日：2018-06-14